Recommendation of the President – Albendazol Micro Labs
On 25 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 48/2025 on the validity of granting reimbursement for the medicinal product Albendazol Micro Labs for the following indications: hydatid disease of the liver caused by Echinococcus multilocularis, hydatid disease of the liver caused by Echinococcus granulosus